Kenji Ichikawa

发表

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Y. Funahashi, J. Matsui, Yu Kato, 2018, Cancer science.

REGULATION OF THE MAMMALIAN STRESS-RESPONSIVE MTK 1 MAPKKK BY GADD 45-LIKE PROTEINS

M. Takekawa, Takanori Nakamura, Kenji Ichikawa, 2011 .

Stress-induced Translation of ATF5 mRNA Is Regulated by the 5′-Untranslated Region*

Shigeru Takahashi, Hidenori Hirose, Yuji Takahashi, 2008, Journal of Biological Chemistry.

Co-stimulatory molecules decide T cell fate through regulations of their invigoration and impairment

K. Ichikawa, Kenji Ichikawa, 2022, bioRxiv.

Discovery of a potent and selective Axl inhibitor in preclinical model.

D. Ito, T. Nakagawa, T. Matsushima, 2021, Bioorganic & medicinal chemistry.

MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during epithelial-mesenchymal transition by regulating the co-repressor CtBP.

J. S. Weng, H. Saito, M. Takekawa, 2015, Molecular cell.

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies

Y. Funahashi, Yu Kato, A. Yokoi, 2021, Cancer Research.

N-terminal Hydrophobic Amino Acids of Activating Transcription Factor 5 (ATF5) Protein Confer Interleukin 1β (IL-1β)-induced Stabilization*

S. Akanuma, M. Kojima, Shigeru Takahashi, 2013, The Journal of Biological Chemistry.

Regulation of stress-activated MAP kinase pathways during cell fate decisions.

Yuji Kubota, Mutsuhiro Takekawa, M. Takekawa, 2011, Nagoya journal of medical science.

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy

Y. Funahashi, J. Matsui, Kenji Ichikawa, 2020, Scientific Reports.

Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

K. Okamoto, J. Matsui, Kenji Ichikawa, 2016 .

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy

Y. Funahashi, J. Matsui, Kenji Ichikawa, 2020, Scientific Reports.

Abstract 1374: Lenvatinib, tri-specific targeted therapy to VEGFR/FGFR/RET, suppresses angiogenesis through the inhibition of both VEGFR and FGFR signaling pathways

Yuji Yamamoto, K. Okamoto, Y. Funahashi, 2015 .